Harald Burkhardt

9.7k total citations
160 papers, 4.7k citations indexed

About

Harald Burkhardt is a scholar working on Rheumatology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Harald Burkhardt has authored 160 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 86 papers in Rheumatology, 65 papers in Immunology and 45 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Harald Burkhardt's work include Rheumatoid Arthritis Research and Therapies (58 papers), Monoclonal and Polyclonal Antibodies Research (42 papers) and Cell Adhesion Molecules Research (38 papers). Harald Burkhardt is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (58 papers), Monoclonal and Polyclonal Antibodies Research (42 papers) and Cell Adhesion Molecules Research (38 papers). Harald Burkhardt collaborates with scholars based in Germany, Sweden and United States. Harald Burkhardt's co-authors include Rikard Holmdahl, Åke Engström, Bettina Sehnert, Beate Böhm, Vivianne Malmström, Kutty Selva Nandakumar, Frank Behrens, Klaus von der Mark, Robert Bockermann and Erik Michaëlsson and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and The Journal of Experimental Medicine.

In The Last Decade

Harald Burkhardt

156 papers receiving 4.6k citations

Peers

Countries citing papers authored by Harald Burkhardt

Since Specialization

Citations

This map shows the geographic impact of Harald Burkhardt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harald Burkhardt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harald Burkhardt more than expected).

Fields of papers citing papers by Harald Burkhardt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Harald Burkhardt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harald Burkhardt. The network helps show where Harald Burkhardt may publish in the future.

Co-authorship network of co-authors of Harald Burkhardt

This figure shows the co-authorship network connecting the top 25 collaborators of Harald Burkhardt. A scholar is included among the top collaborators of Harald Burkhardt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Harald Burkhardt. Harald Burkhardt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Human MHC Class II and Invariant Chain Knock‐in Mice Mimic Rheumatoid Arthritis with Allele Restriction in Immune Response and Arthritis Association 2024 ·Advanced Science ·(unknown), (unknown), (unknown), Outi Sareila, Bingze Xu, (unknown), Zhongwei Xu, (unknown), Ana Coelho, (unknown), Vilma Urbonaviciute, Olov Ekwall, Harald Burkhardt, Rikard Holmdahl	6
2	Therapy targeting antigen-specific T cells by a peptide-based tolerizing vaccine against autoimmune arthritis 2023 ·Proceedings of the National Academy of Sciences ·Vilma Urbonaviciute, (unknown), Bingze Xu, (unknown), (unknown), (unknown), (unknown), Ana Coelho, (unknown), (unknown), Pierre Sabatier, Christian M. Beusch, (unknown), Roman A. Zubarev, Jan Kihlberg, Johan Bäcklund, Harald Burkhardt, Rikard Holmdahl	8
3	Impact of different classes of immune-modulating treatments on B cell-related and T cell-related immune response before and after COVID-19 booster vaccination in patients with immune-mediated diseases and primary immunodeficiency: a cohort study 2023 ·RMD Open ·(unknown), (unknown), Stephanie Dauth, (unknown), Niko Kohmer, Harald Burkhardt, Sandra Ciesek, Gerd Geißlinger, Holger F. Rabenau, Frank Behrens	1
4	Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA) 2022 ·Journal of Clinical Medicine ·(unknown), Ann Christina Foldenauer, (unknown), Rieke Alten, Martin Aringer, Marina Backhaus, Gerd R Burmester, Eugen Feist, Herbert Kellner, Klaus Krueger, Ulf Müller‐Ladner, Andrea Rubbert‐Roth, Hans‐Peter Tony, Siegfried Wassenberg, Harald Burkhardt, Frank Behrens	1
5	A Novel Pro-Inflammatory Mechanosensing Pathway Orchestrated by the Disintegrin Metalloproteinase ADAM15 in Synovial Fibroblasts 2021 ·Cells ·(unknown), Florian Meier, (unknown), Raimund W. Kinne, Beate Böhm, Harald Burkhardt	4
6	THU0165 PROSARA - A PROSPECTIVE, MULTICENTER, NON-INTERVENTIONAL STUDY TO EVALUATE THE SAFETY AND EFFECTIVENESS OF SARILUMAB FOR THE TREATMENT OF ACTIVE RHEUMATOID ARTHRITIS IN REGULAR CARE IN GERMANY 2020 ·Annals of the Rheumatic Diseases ·Eugen Feist, Peer Aries, (unknown), Harald Burkhardt, Inka Albrecht, (unknown), Michael Obermeier, (unknown), Martin Welcker, (unknown), (unknown), N.T. Baerlecken, H-P Tony	1
7	Use of a “critical difference” statistical criterion improves the predictive utility of the Health Assessment Questionnaire-Disability Index score in patients with rheumatoid arthritis 2019 ·BMC Rheumatology ·Frank Behrens, (unknown), Eva C. Schwaneck, Marc Schmalzing, (unknown), (unknown), Hans‐Peter Tony, Harald Burkhardt	11
8	The sneaking ligand approach for cell type-specific modulation of intracellular signalling pathways 2017 ·Clinical Immunology ·Bettina Sehnert, Harald Burkhardt, Stephanie Finzel, Stefan Dübel, Reinhard Voll	2
9	Hautmalignome und immunmodulierende Antirheumatikatherapie 2016 ·Zeitschrift für Rheumatologie ·Harald Burkhardt, Peter Weisenseel, Marc Alexander Radtke, K. Krüger	2
10	Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial 2014 ·Annals of the Rheumatic Diseases ·Josef S Smolen, Paul Emery, Gianfranco Ferraccioli, Włodzimierz Samborski, Francis Bérenbaum, (unknown), (unknown), O. Purcaru, (unknown), Harald Burkhardt	91
11	First in Patient Study of Anti-GM-CSF Monoclonal Antibody (MOR103) in Active Rheumatoid Arthritis: Results of a Phase 1b/2a Randomized, Double-Blind, Placebo-Controlled Trial 2012 ·Data Archiving and Networked Services (DANS) ·Frank Behrens, Mikkel Østergaard, Румен Стоилов, Piotr Wiland, T. Huizinga, (unknown), P. P. Tak, (unknown), Jürgen Rech, Andrea Rubbert‐Roth, Mariusz Korkosz, (unknown), И. А. Зупанец, B Ejbjerg, Jens Geiseler, (unknown), Roman Korolkiewicz, Arndt Schottelius, Harald Burkhardt	9
12	Antibodies to the endoplasmic reticulum-resident chaperones calnexin, BiP and Grp94 in patients with rheumatoid arthritis and systemic lupus erythematosus 2010 ·Lara D. Veeken ·(unknown), Martin Haslbeck, Matthias Englbrecht, Bettina Sehnert, Dirk Mielenz, (unknown), J. Distler, Ruediger B. Müeller, Harald Burkhardt, Georg Schett, (unknown), Barbara G. Fürnrohr	35
13	Visualization and phenotyping of pro-inflammatory antigen-specific T cells during collagen induced arthritis in a mouse with a fixed collagen type II specific transgenic TCR beta chain 2010 ·Arthritis Research & Therapy ·Patrick Merky, Tsvetelina Batsalova, Robert Bockermann, Balik Dzhambazov, Bettina Sehnert, Harald Burkhardt, Johan Bäcklund	6
14	Deletion of LCE3C and LCE3B genes at PSORS4 does not contribute to susceptibility to psoriatic arthritis in German patients 2009 ·Annals of the Rheumatic Diseases ·Ulrike Hüffmeier, Xavier Estivill, Eva Riveira‐Muñoz, Heiko Traupe, Jörg Wendler, Jörg Lohmann, Bernhard Böhm, Harald Burkhardt, André Reis	34
15	ADAM15 modulates outside‐in signalling in chondrocyte–matrix interactions 2008 ·Journal of Cellular and Molecular Medicine ·Beate Böhm, (unknown), Harald Burkhardt	13
16	TNF polymorphisms in psoriasis: Association of psoriatic arthritis with the promoter polymorphism TNF‐857* independent of the PSORS1 risk allele 2007 ·Arthritis & Rheumatism ·Kristian Reich, Ulrike Hüffmeier, Inke R. König, Jesús Lascorz, Jörg Lohmann, Jörg Wendler, Heiko Traupe, Rotraut Mößner, André Reis, Harald Burkhardt	60
17	[Current therapeutic strategy for rheumatoid arthritis]. 2006 ·PubMed ·J. Wollenhaupt, R. Alten, Harald Burkhardt, (unknown), Erika Gromnica‐Ihle, (unknown), K. Krüger, Bernhard Manger, Hanns‐Martin Lorenz, Ulf Müller‐Ladner, (unknown), (unknown), Hans‐Peter Tony, M. Schneider	3
18	Human Monoclonal Rheumatoid Synovial B Lymphocyte Hybridoma with a New Disease-Related Specificity for Cartilage Oligomeric Matrix Protein 2001 ·The Journal of Immunology ·Margarida Souto‐Carneiro, Harald Burkhardt, (unknown), R. Schulte Hermann, Albrecht Otto, (unknown), (unknown), (unknown), Dick Heinegård, Hans Konrad Müller‐Hermelink, Veit Krenn	22
19	Highly enhanced expression of the disintegrin metalloproteinase MDC15 (metargidin) in rheumatoid synovial tissue 2001 ·Arthritis & Rheumatism ·(unknown), Thomas Aigner, Carl Blobel, J R Kalden, Harald Burkhardt	32
20	Treatment of bovine leukaemia virus-infected sheep with suramin: an animal model for the development of antiretroviral compounds. 1989 ·PubMed ·Harald Burkhardt, S. M. Rosenthal, H. A. Rosenthal, (unknown), Erik De Clercq	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact